论文部分内容阅读
目的:通过通心络胶囊对载脂蛋白E基因敲除小鼠[ApoE(-/-)]冠状动脉斑块和心肌病理组织学的干预变化,探究其治疗冠心病(CHD)动脉粥样硬化(AS)的疗效机制。方法:将40只ApoE(-/-)小鼠作为实验组,建立冠状AS模型,随机分为模型组和辛伐他汀组等4组,后者分别给予辛伐他汀及高、中、低剂量的通心络胶囊进行干预8周;另选8只同系的小鼠作为正常对照组。通过观察各组小鼠冠状动脉斑块和心肌病理组织学等指标的变化,探讨通心络胶囊对ApoE(-/-)小鼠AS的调节作用和机制。结果:模型组小鼠冠状动脉病变主要位于心肌内的小分支、心肌细胞、心肌间质,均分为6.63±1.48;辛伐他汀组和通心络胶囊各剂量组冠状动脉及心肌病变较模型组均减轻,其中辛伐他汀组均分为2.62±2.25,通心络胶囊低剂量组均分为4.5±1.71,中剂量组均分为3.12±1.81,高剂量组均分为2.38±2.34。通心络胶囊低剂量组与模型组比较,P<0.05;通心络胶囊中、高剂量组与模型组比较,均为P<0.01;辛伐他汀组与模型组比较,P<0.01;通心络胶囊中、高剂量组与辛伐他汀组比较,P>0.05。结论:通心络胶囊对冠状AS的形成有一定的抑制作用,各剂量组作用强度依次为高、中、低剂量组,其中中、高剂量组与辛伐他汀组作用相当。
OBJECTIVE: To investigate the effect of Tongxinluo capsule on coronary plaque and myocardial histopathology in apolipoprotein E gene knockout mice (ApoE (- / -)] and to explore its therapeutic effect on coronary heart disease (CHD) atherosclerosis (AS) efficacy mechanism. Methods: Forty ApoE (- / -) mice were used as the experimental group. Coronary AS model was established and randomly divided into 4 groups: model group and simvastatin group. Simvastatin and high, Of Tongxinluo capsule for 8 weeks; another 8 homologous mice were selected as normal control group. To investigate the regulatory effect of Tongxinluo capsule on AS in ApoE (- / -) mice by observing the changes of coronary artery plaque and myocardial histopathology in each group. Results: The lesions of coronary artery in the model group were mainly located in the small branches, myocardial cells and myocardial interstitium in the myocardium, which were all divided into 6.63 ± 1.48. The coronary and myocardial lesions of simvastatin group and Tongxinluo capsule were significantly different Group were all reduced 2.62 ± 2.25, Tongxinluo capsule low dose group were divided into 4.5 ± 1.71, middle dose group were divided into 3.12 ± 1.81, high dose group were divided into 2.38 ± 2.34. Tongxinluo capsule low-dose group compared with the model group, P <0.05; Tongxinluo capsule, high-dose group compared with the model group, were P <0.01; simvastatin group and model group, P <0.01; Xinluo capsule, high-dose group and simvastatin group, P> 0.05. CONCLUSION: Tongxinluo capsule can inhibit the formation of coronary AS. The intensity of each dose group is high, medium and low dose group, and the middle and high dose group is similar to simvastatin group.